Researchers at Cima Universidad de Navarra have identified IRF2 as a key transcription factor in multiple myeloma development. The study reveals that IRF2 expression levels can stratify patients and predict response to treatment, potentially leading to improved therapeutic outcomes.
A Spanish research study has described the composition of the immune system in blood samples from patients with multiple myeloma and found that altered immune cells influence vaccine efficacy. The study reveals a more severe immune suppression in patients with multiple myeloma compared to those with other tumors.
A long non-coding RNA called lncREST has been identified as a crucial component of the stress response during DNA replication. Its absence leads to impaired stress signalling, resulting in severe DNA defects and cell death. The discovery opens up new avenues for developing anti-tumour therapies.
Spanish researchers successfully inhibited TIM-3, an immune checkpoint molecule, promoting a proinflammatory microenvironment that boosts the antitumor response. This breakthrough could guide clinical trials for diffuse intrinsic stem glioma (DIPG), the leading cause of death in pediatric cancer.
Researchers developed a calculator to identify patients with multiple myeloma and primary systemic amyloidosis who have a more benign profile, allowing for personalized treatment. The tool predicts survival based on clinical-biological characteristics and has been validated in international series.
Researchers at Cima Universidad de Navarra identified LAMC2 as a key gene in pancreatic cancer development. Inhibiting this gene, combined with existing drugs, increases antitumor effect in 3D models.